Science Corporation has closed a $230 million Series C round, bringing its total funding to roughly $490 million since the company was founded in 2021. The round was oversubscribed, with investor demand exceeding the capital the company sought. Lightspeed Venture Partners, Khosla Ventures, Y Combinator, IQT, and Quiet Capital all participated, each of them returning investors from previous rounds.
The deal values Science at a moment of genuine commercial traction. The company plans to launch PRIMA, its brain-computer interface retinal implant, in Europe later this year. If that timeline holds, Science will become the first BCI company to place a vision restoration product on the market.
A Device That Has Already Changed How Vision Restoration Is Understood
PRIMA works by replacing damaged photoreceptors in the retina with a wireless implant that processes light signals and sends them directly to the brain. In clinical trials, it was the only treatment to restore form vision in patients blinded by advanced dry age-related macular degeneration. The results were published as a peer-reviewed paper in The New England Journal of Medicine and appeared on the cover of Time magazine, two markers of recognition that are rare for early-stage medical technology.
The trial enrolled 38 patients with advanced dry AMD. Among them, 80 percent showed meaningful improvement in visual acuity and could read letters, numbers, and words after treatment. Science has since submitted a CE mark application to the European Union and applied to the U.S. Food and Drug Administration for regulatory clearance, running both processes in parallel.
“We are building a company which will offer patients hope beyond the limitations of traditional medicine,” said Max Hodak, cofounder and CEO of Science. “By engaging the brain directly as an information processing organ, we are able to achieve much greater effect sizes and drive unprecedented clinical impact. We are deeply committed to research and new technologies that can provide treatment options where none existed before, and which will fundamentally change and improve lives.”
From Clinical Proof to Commercial Reality
The Series C proceeds will be used to push PRIMA through its European commercial launch and to scale the infrastructure needed to support it. That includes expanding the company’s manufacturing capacity, growing its research operations, and advancing two additional platform technologies: its Biohybrid neural interface and its Vessel perfusion system.
Science is also investing in its MEMS Foundry and BCI Ecosystem businesses, two units that sit adjacent to its core implant work and that the company sees as part of a longer-term strategy. The broader goal is to build a vertically integrated neural engineering company, not just a single-product medical device maker. Darius Shahida, Science’s Chief Strategy Officer, put it plainly: “Our imperative is to become the first BCI company to scale and achieve profitability.”
Expanding Into Inherited Retinal Disease
Alongside the funding announcement, Science disclosed that it is expanding its PRIMA clinical trial program to cover additional retinal conditions. The two new targets are Stargardt disease and retinitis pigmentosa, which are among the leading causes of inherited vision loss in young adults. Stargardt disease affects roughly 1 in 10,000 people; retinitis pigmentosa affects approximately 1 in 4,000.
These are conditions with no approved treatments capable of restoring lost vision, which makes this expansion clinically significant. The first new trials will be led by Dr. Matthew Simunovic, MB BChir, PhD, a specialist in retinal disease therapy and prosthetic vision research, at the Sydney Eye Hospital in Australia.
About Science Corporation
Science Corporation was founded in 2021 by Max Hodak, who previously co-founded Neuralink. The company is headquartered in Alameda, California, and describes its mission as restoring and extending life by moving beyond the limits of traditional biology. It operates as a full-stack neural engineering company, which means it develops both the hardware and the surrounding software and delivery systems itself, rather than licensing components from third parties.
The company’s portfolio spans retinal BCI technology, Biohybrid neural interfaces, Vessel perfusion platforms, a MEMS Foundry, and a broader BCI Ecosystem business. This structure gives Science more control over its development timeline and cost structure than most early-stage medical device companies, and it has been a consistent feature of how the company presents itself to investors.
“The strength and caliber of this syndicate reflects both the urgency of the problems we are addressing and the credibility of our execution so far,” said Shahida. “With this capital, we are focused on commercialization and delivering real-world clinical impact.”
Investor Profile and Funding History
The Series C was led by a syndicate of investors who had all backed the company in prior rounds. Lightspeed Venture Partners, Khosla Ventures, Y Combinator, IQT, and Quiet Capital participated, and the round closed oversubscribed. With this raise, Science’s total capital stands at approximately $490 million since its 2021 founding.
The investor composition reflects a mix of traditional venture capital and mission-oriented funds. IQT, in particular, is a nonprofit strategic investor that focuses on technologies relevant to national security, an unusual presence in a medical device round and one that speaks to how BCI technology is being viewed beyond healthcare circles.
